| Identification | Back Directory | [Name]
Rigosertib sodium | [CAS]
592542-60-4 | [Synonyms]
Novonex
ON 01910 Na
ON 01910 sodium
RIGOSERTIB SODIUM
Rigosertib sodium（E）
RIGOSERTIB SODIUM (ON-01910 SODIUM)
Rigosertib sodium - ON01910 sodium | Estybon
ON-01910 SODIUM;ON01910 SODIUM;ON01910 SODIUM
(E)-2,4,6-Trimethoxystyryl 3-[(carboxymethyl)amino]-4-methoxybenzyl sulfone sodium salt
Glycine, N-[2-Methoxy-5-[[[(1E)-2-(2,4,6-triMethoxyphenyl)ethenyl]sulfonyl]Methyl]phenyl]-, sodiuM Slat | [Molecular Formula]
C21H24NNaO8S | [MDL Number]
MFCD11655911 | [MOL File]
592542-60-4.mol | [Molecular Weight]
473.472 |
| Hazard Information | Back Directory | [Definition]
ChEBI: Rigosertib sodium is the sodium salt of rigosertib. It is an anti-cancer agent which has been granted Orphan Drug Designation by the FDA for use in patients with myelodysplastic syndromes (MDS). It has a role as a microtubule-destabilising agent, an antineoplastic agent, an EC 2.7.11.21 (polo kinase) inhibitor and an apoptosis inducer. It contains a rigosertib(1-). |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|